Nyman John A
Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
MDM Policy Pract. 2018 Apr 10;3(1):2381468318765162. doi: 10.1177/2381468318765162. eCollection 2018 Jan-Jun.
A 2nd edition of has now been published by a group of medical decision-making experts known collectively as the 2nd Panel. This is a critical review of the recommendations for how to deal with costs in cost-effectiveness analysis, recommendations that are contained in Chapter 8 of that edition, titled "Estimating Costs and Valuations of Non-Health Benefits in Cost-Effectiveness Analysis," authored primarily but not exclusively by Anirban Basu. This review focuses on the correspondence between the costs in the numerator of the incremental cost-effectiveness ratio (ICER) and what is measured in the denominator of the ICER by the quality-adjusted life years (QALYs). Although it raises a number of issues regarding what is actually being measured in the numerator and denominator of the ICER, it primarily challenges the 2nd Panel's recommendation that the costs of non-health consumption in any additional years of life generated by the intervention in question be accounted for in the numerator, even though no measures of the benefits are included in the QALYs in the denominator. This review is adapted from a review of the entire 2 edition that was sent to the 2 Panel steering committee on January 8, 2016.
由一群统称为第二小组的医学决策专家共同撰写的第二版现已出版。这是对成本效益分析中如何处理成本的建议的批判性审视，这些建议包含在该版本的第8章中，章名为“成本效益分析中成本估算与非健康效益估值”，主要作者是阿尼尔班·巴苏，但并非唯一作者。该审视聚焦于增量成本效益比（ICER）分子中的成本与ICER分母中通过质量调整生命年（QALYs）所衡量内容之间的对应关系。尽管它提出了一些关于ICER分子和分母实际所衡量内容的问题，但主要挑战了第二小组的建议，即在所讨论干预措施带来的任何额外生命年份中非健康消费的成本应计入分子，即便分母中的QALYs并未纳入效益衡量。本审视改编自2016年1月8日发送给第二小组指导委员会的对整个第二版的审视。
